Folkman Laboratory

LIke ThisLIke ThisLIke ThisLIke ThisLIke This

The primary focus of the Folkman laboratory is on selectively controlling the process of angiogenesis to prevent and treat disease. Research in this laboratory and in others within the Vascular Biology Program is focused on elucidating the molecular mechanisms that both initiate and suppress angiogenesis. Once identified, such processes become potential targets for the development of diagnostic tests and therapeutic drugs for conditions ranging from obesity to eye diseases to cancer.

More than 50 such products are now in clinical trials, including a urine test to identify preclinical malignancies and several anti-angiogenic compounds. One anti-angiogenic drug, Avastin, has been approved by the FDA, as part of combination chemotherapy for first-line treatment of metastatic colorectal cancer. 

Request an Appointment

If this is a medical emergency, please dial 9-1-1. This form should not be used in an emergency.

Patient Information
Date of Birth:
Contact Information
Appointment Details
Send RequestIf you do not see the specialty you are looking for, please call us at: 617-355-6000.International visitors should call International Health Services at +1-617-355-5209.
Please complete all required fields

This department is currently not accepting appointment requests online. Please call us at: 617-355-6000. International +1-617-355-6000.

This department is currently not accepting appointment requests online. Please call us at: 617-355-6000. International +1-617-355-6000.

Thank you.

Your request has been successfully submitted

You will be contacted within 1 business day.

If you have questions or would like more information, please call:

617-355-6000 +1-617-355-6000
Find a Doctor
Search by Clinician's Last Name or Specialty:
Select by Location:
Search by First Letter of Clinician's Last Name: *ABCDEFGHIJKLMNOPQRSTUVWXYZ
More optionsSearch
Condition & Treatments
Search for a Condition or Treatment:
View allSearch
The future of pediatrics will be forged by thinking differently, breaking paradigms and joining together in a shared vision of tackling the toughest challenges before us.”
- Sandra L. Fenwick, President and CEO